fda compounding semaglutide enforcement news november 2025 New project announcement: HHS‑OIG is taking a closer look at FDA's oversight of compounded GLP‑1 drugs. Although shortages ended in 2025, some facilities may still be producing these drugs at scale. Our Novo pressures GLP-1 compounders as

Similarly, another study found a higher rate of progression of proliferative diabetic retinopathy as well as risk of new-onset diabetic macular edema with GLP-1 RAs compared to SGLT-2is

If you're interested in optimizing your entire weight loss therapynot just storage practicesconsider adding the PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) to understand which peptide pathways your body responds to most effectively

provide substantial contribution to interpretation of data, critically reviewed the manuscript, contribute an important intellectual content and gave final approval of the manuscript

They represent genuine cellular protection during a period of significant physical change

Strong lifestyle changes and, for some people, a maintenance dose help reduce that risk

2023 Aug 10;389(6):514-526